Although the estimated prevalence of BRAF V600 mutations in GBM is low (about 2%) [49,50], given its significant therapeutic implication, routine screening for BRAF mutations should also be strongly encouraged in this setting. The gene discussed is BRAF; the disease is glioblastoma.